Arbutus Biopharma Corp (ABUS)
3.63
-0.02
(-0.55%)
USD |
NASDAQ |
Nov 14, 16:00
3.63
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Research and Development Expense (Quarterly): 14.27M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 14.27M |
| June 30, 2024 | 15.55M |
| March 31, 2024 | 15.40M |
| December 31, 2023 | 17.56M |
| September 30, 2023 | 20.17M |
| June 30, 2023 | 17.69M |
| March 31, 2023 | 18.28M |
| December 31, 2022 | 22.95M |
| September 30, 2022 | 20.06M |
| June 30, 2022 | 22.94M |
| March 31, 2022 | 18.46M |
| December 31, 2021 | 19.21M |
| September 30, 2021 | 16.71M |
| June 30, 2021 | 15.80M |
| March 31, 2021 | 13.78M |
| December 31, 2020 | 16.39M |
| September 30, 2020 | 12.06M |
| June 30, 2020 | 10.46M |
| March 31, 2020 | 10.42M |
| December 31, 2019 | 12.42M |
| September 30, 2019 | 17.73M |
| June 30, 2019 | 12.74M |
| March 31, 2019 | 14.71M |
| December 31, 2018 | 11.06M |
| September 30, 2018 | 16.57M |
| Date | Value |
|---|---|
| June 30, 2018 | 16.36M |
| March 31, 2018 | 13.95M |
| December 31, 2017 | 17.82M |
| September 30, 2017 | 15.54M |
| June 30, 2017 | 15.44M |
| March 31, 2017 | 13.87M |
| December 31, 2016 | 17.16M |
| September 30, 2016 | 15.74M |
| June 30, 2016 | 15.22M |
| March 31, 2016 | 13.14M |
| December 31, 2015 | 14.90M |
| September 30, 2015 | 16.35M |
| June 30, 2015 | 9.69M |
| March 31, 2015 | 10.56M |
| December 31, 2014 | 11.90M |
| September 30, 2014 | 9.309M |
| June 30, 2014 | 9.298M |
| March 31, 2014 | 8.204M |
| December 31, 2013 | 6.971M |
| September 30, 2013 | 5.506M |
| June 30, 2013 | 4.914M |
| March 31, 2013 | 4.067M |
| December 31, 2012 | 7.059M |
| September 30, 2012 | 3.152M |
| June 30, 2012 | 3.512M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
10.42M
Minimum
Mar 2020
22.95M
Maximum
Dec 2022
16.53M
Average
16.55M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Amicus Therapeutics Inc | 26.16M |
| Ionis Pharmaceuticals Inc | 219.76M |
| GlycoMimetics Inc | 6.286M |
| FibroGen Inc | 34.11M |